Moleculin Biotech Inc (LTS:0K2H) Stock News, Headlines & Updates
Moleculin Biotech Inc Stock News from GuruFocus
- 1
Jun 14, 2024
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial
PRNewswire • 8:00am
Jun 12, 2024
Moleculin to Present at the Virtual Investor Pitch Conference
PRNewswire • 9:00am
Jun 05, 2024
Moleculin to Participate in the Virtual Investor Lunch Break Series
PRNewswire • 8:00am
May 16, 2024
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress
PRNewswire • 8:00am
May 15, 2024
Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)
PRNewswire • 8:00am
May 14, 2024
Moleculin Biotech Inc (MBRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances and Financial Health
GuruFocus Research • 1:00am
Q1 2024 Moleculin Biotech Inc Earnings Call Transcript
GuruFocus Research • 11:02pm
May 13, 2024
Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update
PRNewswire • 7:00am
May 09, 2024
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
PRNewswire • 8:00am
May 08, 2024
Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast
PRNewswire • 8:00am
May 07, 2024
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
PRNewswire • 8:00am
May 02, 2024
Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024
PRNewswire • 9:00am
May 01, 2024
Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin
PRNewswire • 8:01am
Apr 25, 2024
Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
ACCESSWIRE • 11:00am
Apr 18, 2024
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
PRNewswire • 8:00am
Apr 10, 2024
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
PRNewswire • 8:00am
Mar 28, 2024
Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
PRNewswire • 10:00am
Mar 27, 2024
Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
PRNewswire • 9:00am
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
PRNewswire • 9:00am
Mar 26, 2024
Q4 2023 Moleculin Biotech Inc Earnings Call Transcript
GuruFocus Research • 11:00pm
Mar 25, 2024
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
PRNewswire • 7:00am
- 1
Show
Entries
Headlines
Total 0- 1
No recent news